Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
Abstract Immunotherapy targeting GD2 is a primary treatment for patients with high‐risk neuroblastoma. Dinutuximab is a monoclonal antibody with great clinical promise but is limited by side effects such as severe pain. Local delivery has emerged as a potential mechanism to deliver higher doses of t...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2936 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849330506527670272 |
|---|---|
| author | Kimberly J. Ornell Jordan S. Taylor Jasmine Zeki Naohiko Ikegaki Hiroyuki Shimada Jeannine M. Coburn Bill Chiu |
| author_facet | Kimberly J. Ornell Jordan S. Taylor Jasmine Zeki Naohiko Ikegaki Hiroyuki Shimada Jeannine M. Coburn Bill Chiu |
| author_sort | Kimberly J. Ornell |
| collection | DOAJ |
| description | Abstract Immunotherapy targeting GD2 is a primary treatment for patients with high‐risk neuroblastoma. Dinutuximab is a monoclonal antibody with great clinical promise but is limited by side effects such as severe pain. Local delivery has emerged as a potential mechanism to deliver higher doses of therapeutics into the tumor bed, while limiting systemic toxicity. We aim to deliver dinutuximab locally in a lyophilized silk fibroin foam for the treatment of an orthotopic neuroblastoma mouse model. Dinutuximab‐loaded silk fibroin foams were fabricated through lyophilization. In vitro release profile and bioactivity of the release through complement‐dependent cytotoxicity were characterized. MYCN‐amplified neuroblastoma cells (KELLY) were injected into the left gland of mice to generate an orthotopic neuroblastoma model. Once the tumor volume reached 100 mm3, dinutuximab‐, human IgG‐, or buffer‐loaded foams were implanted into the tumor and growth was monitored using high‐resolution ultrasound. Post‐resection histology was performed on tumors. Dinutuximab‐loaded silk fibroin foams exhibited a burst release, with slow release thereafter in vitro with maintenance of bioactivity. The dinutuximab‐loaded foam significantly inhibited xenograft tumor growth compared to IgG‐ and buffer‐loaded foams. Histological analysis revealed the presence of dinutuximab within the tumor and neutrophils and macrophages infiltrating into dinutuximab‐loaded silk foam. Tumors treated with local dinutuximab had decreased MYCN expression on histology compared to control or IgG‐treated tumors. Silk fibroin foams offer a mechanism for local release of dinutuximab within the neuroblastoma tumor. This local delivery achieved a significant decrease in tumor growth rate in a mouse orthotopic tumor model. |
| format | Article |
| id | doaj-art-01e8782bbfaf4100ba124fadbc3a0521 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-01e8782bbfaf4100ba124fadbc3a05212025-08-20T03:46:54ZengWileyCancer Medicine2045-76342020-04-01982891290310.1002/cam4.2936Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma modelKimberly J. Ornell0Jordan S. Taylor1Jasmine Zeki2Naohiko Ikegaki3Hiroyuki Shimada4Jeannine M. Coburn5Bill Chiu6Department of Biomedical Engineering Worcester Polytechnic Institute Worcester MA USADepartment of Surgery Division of Pediatric Surgery Stanford University Stanford CA USADepartment of Surgery Division of Pediatric Surgery Stanford University Stanford CA USADepartment of Anatomy and Cell Biology University of Illinois at Chicago Chicago IL USADepartment of Pathology and Laboratory Medicine University of Southern California Los Angeles CA USADepartment of Biomedical Engineering Worcester Polytechnic Institute Worcester MA USADepartment of Surgery Division of Pediatric Surgery Stanford University Stanford CA USAAbstract Immunotherapy targeting GD2 is a primary treatment for patients with high‐risk neuroblastoma. Dinutuximab is a monoclonal antibody with great clinical promise but is limited by side effects such as severe pain. Local delivery has emerged as a potential mechanism to deliver higher doses of therapeutics into the tumor bed, while limiting systemic toxicity. We aim to deliver dinutuximab locally in a lyophilized silk fibroin foam for the treatment of an orthotopic neuroblastoma mouse model. Dinutuximab‐loaded silk fibroin foams were fabricated through lyophilization. In vitro release profile and bioactivity of the release through complement‐dependent cytotoxicity were characterized. MYCN‐amplified neuroblastoma cells (KELLY) were injected into the left gland of mice to generate an orthotopic neuroblastoma model. Once the tumor volume reached 100 mm3, dinutuximab‐, human IgG‐, or buffer‐loaded foams were implanted into the tumor and growth was monitored using high‐resolution ultrasound. Post‐resection histology was performed on tumors. Dinutuximab‐loaded silk fibroin foams exhibited a burst release, with slow release thereafter in vitro with maintenance of bioactivity. The dinutuximab‐loaded foam significantly inhibited xenograft tumor growth compared to IgG‐ and buffer‐loaded foams. Histological analysis revealed the presence of dinutuximab within the tumor and neutrophils and macrophages infiltrating into dinutuximab‐loaded silk foam. Tumors treated with local dinutuximab had decreased MYCN expression on histology compared to control or IgG‐treated tumors. Silk fibroin foams offer a mechanism for local release of dinutuximab within the neuroblastoma tumor. This local delivery achieved a significant decrease in tumor growth rate in a mouse orthotopic tumor model.https://doi.org/10.1002/cam4.2936Ch14.18dinutuximabimmunotherapylocal deliveryneuroblastomasilk fibroin |
| spellingShingle | Kimberly J. Ornell Jordan S. Taylor Jasmine Zeki Naohiko Ikegaki Hiroyuki Shimada Jeannine M. Coburn Bill Chiu Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model Cancer Medicine Ch14.18 dinutuximab immunotherapy local delivery neuroblastoma silk fibroin |
| title | Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model |
| title_full | Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model |
| title_fullStr | Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model |
| title_full_unstemmed | Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model |
| title_short | Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model |
| title_sort | local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model |
| topic | Ch14.18 dinutuximab immunotherapy local delivery neuroblastoma silk fibroin |
| url | https://doi.org/10.1002/cam4.2936 |
| work_keys_str_mv | AT kimberlyjornell localdeliveryofdinutuximabfromlyophilizedsilkfibroinfoamsfortreatmentofanorthotopicneuroblastomamodel AT jordanstaylor localdeliveryofdinutuximabfromlyophilizedsilkfibroinfoamsfortreatmentofanorthotopicneuroblastomamodel AT jasminezeki localdeliveryofdinutuximabfromlyophilizedsilkfibroinfoamsfortreatmentofanorthotopicneuroblastomamodel AT naohikoikegaki localdeliveryofdinutuximabfromlyophilizedsilkfibroinfoamsfortreatmentofanorthotopicneuroblastomamodel AT hiroyukishimada localdeliveryofdinutuximabfromlyophilizedsilkfibroinfoamsfortreatmentofanorthotopicneuroblastomamodel AT jeanninemcoburn localdeliveryofdinutuximabfromlyophilizedsilkfibroinfoamsfortreatmentofanorthotopicneuroblastomamodel AT billchiu localdeliveryofdinutuximabfromlyophilizedsilkfibroinfoamsfortreatmentofanorthotopicneuroblastomamodel |